Short answer
Perspective Therapeutics, Inc. (CATX) filed an 8-K current report with the SEC on October 23, 2026 reporting Item 8.01 (Other Events), Item EX-99.1 (Exhibit EX-99.1), Item EX-99.2 (Exhibit EX-99.2). Updated interim Phase 1/2a results for [²¹²Pb]VMT-α-NET in unresectable or metastatic SSTR2-expressing neuroendocrine tumors.
Perspective Therapeutics, Inc. 8-K event analysis
AI summary of each reported item and its exhibits
Item 8.01 · Other Events
- Updated interim Phase 1/2a results for [²¹²Pb]VMT-α-NET in unresectable or metastatic SSTR2-expressing neuroendocrine tumors
- Data presented at ESMO Congress 2026, potentially informing clinical efficacy and safety perceptions
- Press release and presentation filed as Exhibits 99.1 and 99.2 for detailed trial results
Item EX-99.1 · Exhibit EX-99.1
- Phase 1/2a data support VMT-α-NET advancement, with ORR 33% at 5.0 mCi and 50% at 6.0 mCi
- Durable disease control: PFS 72% at 18 months across all cohorts
- Favorable safety profile: no DLTs, treatment-related discontinuations, or Grade 4/5 adverse events among 68 patients
- Phase 3 site-start preparations targeted around year-end 2026, with initiation expected in 2027 after FDA alignment
- Key risk: interim, non-randomized results remain subject to confirmation and regulatory approval
Item EX-99.2 · Exhibit EX-99.2
- Phase 1/2a study evaluating bamzireotide navoxetan’s therapeutic window
- Clinical program remains ongoing, making safety and dosing data key upcoming catalysts
- Exhibit title provides no efficacy, safety, enrollment, or financial results for investor assessment
Generated from the filing text and exhibits; verify against the original. What 8-K item codes mean
Other Perspective Therapeutics, Inc. 8-K filings
Get the next CATX 8-K as it lands
Follow CATX for push alerts, or ask the research agent what this filing means.